We’re excited to announce that our BRiDGECAR™ T-cell platform has been selected for presentation at two premier scientific meetings in 2025. These dual recognitions reinforce the broad potential of our modular, precision-guided CAR-T platform to address high-unmet-need indications in haematological cancers and in solid tumours.
The International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting accepted our first abstract, “BRiDGECAR™ Technology for the Treatment of Hematological and Solid Cancers”. The abstract highlights the platform’s versatility, showing potent activity across blood and solid tumours including mantel cell lymphoma, multiple myeloma, neuroblastoma, prostate, and ovarian cancers. The split CAR design enables adaptable targeting and generates younger, stem-like T cell populations — addressing key limitations of current-generation CAR therapies. We were pleased to also be selected for the Poster session.
The European Hematology Association (EHA) 2025 Annual Congress has accepted our second abstract, “A Novel Modular CAR-T Cell Therapy Shows Promising Advantages Over Conventional CAR-T Cells for the Treatment of Acute Myeloid Leukemia,” and also awarded us a prestigious 15-minute oral presentation as well. This study demonstrates how BRiDGECAR™ T-cells outperform conventional CAR-Ts in AML models, offering superior cytotoxicity, better fitness, and long-term persistence via a modular, therapeutic antibody-adaptor approach.
We are excited by the progress we have made on the BRiDGECAR™ platform over the last few years, and delighted to be able to share our results with clinicians and other colleagues in the field.
